amantadine has been researched along with Fatigue Syndrome, Chronic in 3 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Fatigue Syndrome, Chronic: A syndrome characterized by persistent or recurrent fatigue, diffuse musculoskeletal pain, sleep disturbances, and subjective cognitive impairment of 6 months duration or longer. Symptoms are not caused by ongoing exertion; are not relieved by rest; and result in a substantial reduction of previous levels of occupational, educational, social, or personal activities. Minor alterations of immune, neuroendocrine, and autonomic function may be associated with this syndrome. There is also considerable overlap between this condition and FIBROMYALGIA. (From Semin Neurol 1998;18(2):237-42; Ann Intern Med 1994 Dec 15;121(12): 953-9)
| Excerpt | Relevance | Reference |
|---|---|---|
| "L-Carnitine is a safe and very well tolerated medicine which improves the clinical status of CFS patients." | 2.68 | Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome. ( Plioplys, AV; Plioplys, S, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Plioplys, AV | 1 |
| Plioplys, S | 1 |
| Bowman, MA | 1 |
| Kirk, JK | 1 |
| Michielutte, R | 1 |
| Preisser, JS | 1 |
| Wiggs, JW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940] | Phase 3 | 120 participants (Actual) | Interventional | 2018-05-28 | Active, not recruiting | ||
| A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525] | Phase 3 | 59 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for amantadine and Fatigue Syndrome, Chronic
| Article | Year |
|---|---|
Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome.
Topics: Amantadine; Antiviral Agents; Carnitine; Cross-Over Studies; Fatigue Syndrome, Chronic; Humans; Neur | 1997 |
Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome.
Topics: Amantadine; Antiviral Agents; Carnitine; Cross-Over Studies; Fatigue Syndrome, Chronic; Humans; Neur | 1997 |
Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome.
Topics: Amantadine; Antiviral Agents; Carnitine; Cross-Over Studies; Fatigue Syndrome, Chronic; Humans; Neur | 1997 |
Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome.
Topics: Amantadine; Antiviral Agents; Carnitine; Cross-Over Studies; Fatigue Syndrome, Chronic; Humans; Neur | 1997 |
Use of amantadine for chronic fatigue syndrome.
Topics: Adult; Amantadine; Antidepressive Agents; Cross-Over Studies; Fatigue Syndrome, Chronic; Female; Hum | 1997 |
1 other study available for amantadine and Fatigue Syndrome, Chronic
| Article | Year |
|---|---|
Amantidine, the old anti-Parkinson medication, being useful in the fatigue syndrome that often accompanies multiple sclerosis.
Topics: Amantadine; Fatigue; Fatigue Syndrome, Chronic; Humans; Male; Middle Aged; Multiple Sclerosis; Parki | 1991 |